Safety before visibility

An aesthetic procedure does not begin with the first incision. It begins with a decision. The quality of that decision is reflected in the care with which the indication, practitioner, team, infrastructure, risks and long-term strategy have been examined. For internationally mobile principals, selecting a familiar, available or frequently recommended name is therefore insufficient.

Online reviews, personal recommendations, television appearances and social-media presence may create visibility. They do not establish procedure-specific experience or the ability to manage complications. Professional representatives with legal, organisational or commercial expertise remain essential, but they cannot replace specialist medical judgement. Independent review by specialists in the relevant discipline adds the clinical depth required for a defensible decision.

In Phase 1, UHNW Aesthetics provides general criteria and a framework for review; it does not assess individual cases. The evidence supporting confidence in a particular decision is examined only in Phase 2 by a legally licensed physician whom the Principal freely chooses and directly appoints. The advantage is not a wider choice, but a more exacting examination of the choice already made or under consideration.

Transparency RegisterTR 06TR 07

Even the most careful medical review cannot exclude a complication with absolute certainty. Residual risk is inherent in every medical decision and cannot be eliminated by reputation or a high treatment price.

The relevant distinction is therefore not between risk and no risk, but between unexamined risk and systematically reduced risk. Medical due diligence reduces avoidable gaps in information, exposes unsupported assumptions and provides a more robust basis for the individual decision.

Intensive review is not a mass-market service. It may require the time of international specialists, multi-stage analysis, discreet data processes, an individual strategy and cross-border continuity. Access to that depth therefore follows a clearly defined engagement framework.

Transparency RegisterTR 07TR 05

Anaesthesia, assistance, nursing, postoperative surveillance and availability in the event of a complication form a single safety chain. Qualifications, responsibilities and actual availability of the team are therefore examined alongside the operating environment, hygiene systems, emergency equipment, transfer options, documentation and material traceability.

An exclusive address or luxurious presentation does not demonstrate medical resilience. What matters is the structure behind the visible façade and whether it corresponds to the risk profile of the planned intervention.

Care does not end when the patient leaves the clinic. Generic consent forms only partly capture individual, anaesthetic, infrastructural and logistical risks. For internationally mobile principals, travel, length of stay, care after returning home and long-term responsibility for imaging, implant surveillance, delayed complications and possible revision must also be considered.

Transparency RegisterTR 07

General guidance may be insufficient where there are complex previous procedures, unusual anatomy, several treatment options or a highly individual risk profile. In such cases, the first step is a strategy and process plan defining the questions, required records, disciplines involved, information scope, sequence and form of the result.

Family Offices, agencies and professional representatives need not disclose their UHNW clients’ names during institutional pre-validation. They establish their organisation, role and an existing professional engagement without identifying the client. In Phase 2, medical information is shared only with the Principal’s authorisation through the directly appointed physician’s professional channels. Confidentiality, purpose-appropriate pseudonymisation or anonymisation and data minimisation remain essential.

Every recipient of case information is named in advance, with their function, information scope and review question. The Phase 2 medical file remains exclusively within the directly appointed physician’s professional system; UHNW Aesthetics neither receives nor maintains it. Identifying information is separated where appropriate and processed only to the extent required. The protected personal and financial pre-validation of private applicants remains separate from subsequent physician-led case review.

Transparency RegisterTR 08

Following successful validation and operational activation, users receive access to general Phase 1 information and review criteria relevant to their area of concern. An institutional contact explains the process and the distinction between general information and individual medicine. Access approval does not initiate a personal case assessment. Such an assessment begins only when a freely chosen, legally licensed physician accepts a new direct Phase 2 mandate from the Principal. By appointment, the introduction may take place online or in person, subject to the agreed scope and security requirements.

UHNW Aesthetics is an internationally active non-profit organisation led by Prof. Dr. med. A. Altintas, M.Sc., a specialist in plastic and aesthetic surgery. Its remit is the general institutional Phase 1 review framework. It does not provide treatment, assess individual medical cases, maintain Phase 2 medical files or receive medical Phase 2 fees. Individual review of the indication, practitioner, team, infrastructure, risks and long-term strategy is solely the responsibility of the directly appointed Phase 2 physician. The reviewing physician does not perform the planned procedure; treatment responsibility remains with the freely chosen treating physician.

The outcome of a review is not necessarily approval. It may call for additional evidence, further conditions, a revised strategy, different timing or abandonment of the original plan. This is precisely where independence becomes visible: the review does not depend on a treatment proceeding.

Transparency RegisterTR 03TR 08